Saturday 17 October 2026
Export SPRY’s income statement to Excel — free account
ARS Pharmaceuticals, Inc.
SPRY Healthcare Biotechnology
ARS Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $84.3 million, down 5.46% from fiscal 2024. In the quarter to June 2026, revenue grew 114.2%, EPS fell 37.0%, free cash flow fell 53.7% and total debt rose 138.5%, each against the same quarter a year earlier.
4.02
0.05
−1.23%
Follow SPRY
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
1 | — | — | — |
+8 more TTM periods Free account |
| (210.37%) | (136.47%) | (92.38%) | (45.89%) | ||
| (76.54%) | (64.42%) | (50.50%) | (27.10%) | ||
ROIC |
(335.65%) | (401.19%) | (296.82%) | (204.70%) | |
Return on Tangible Assets |
(141.07%) | (100.08%) | (69.05%) | (27.66%) | |
Average Days of Receivables |
146.21 | 105.69 | 109.78 | 93.19 | |
Free Cash Flow per Share |
(1.98) | (1.76) | (1.89) | (0.87) | |
Free Cash Flow |
(196.40) | (175.07) | (186.56) | (86.02) | |
Capital Expenditures |
— | — | (15.70) | (0.64) | |
| Other line items | |||||
Cash ROIC |
(59.89%) | (40.39%) | (35.35%) | (14.24%) | |
Accounts Receivable Turnover |
3.25 | 5.21 | 5.03 | 7.67 | |
Accounts Payable Turnover |
0.64 | 0.68 | 0.67 | 0.46 | |
Inventory Turnover |
3.28 | 3.18 | 3.01 | 3.56 | |
Average Days of Payables |
651.26 | 687.72 | 678.21 | 1,200.30 | |
Days of Inventory on Hand |
127.45 | 125.64 | 149.57 | 187.69 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
13.02% | 14.71% | 15.64% | 8.94% | |
Selling, General and Administrative Expense of Revenue |
243.30% | 263.90% | 273.05% | 144.05% | |
Share Based Compensation of Revenue |
26.72% | 24.47% | 26.22% | 14.44% | |
Interest Coverage |
(33.98) | (51.22) | — | — | |
Operating CF/Net income |
0.91 | 0.88 | 1.00 | 1.07 | |
Depreciation/Fixed assets |
(1.01) | (1.34) | (1.69) | (4.21) | |
Capex/Depreciation |
0.00 | 0.00 | 3.78 | 0.13 | |
Revenue per Share |
1.18 | 1.00 | 0.86 | 1.44 | |
Operating CF per Share |
(1.98) | (1.76) | (1.73) | (0.86) | |
Capex per Share |
0.00 | 0.00 | (0.16) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.19 | 0.00 |
Columns are period end dates